PT1654286E - Anticorpo anti-cd4 humanizado com propriedades imunossupressoras - Google Patents

Anticorpo anti-cd4 humanizado com propriedades imunossupressoras Download PDF

Info

Publication number: PT1654286E
Authority: PT; Portugal
Prior art keywords: antibody; humanized anti; immunosuppressive properties; sequence; cdrs
Prior art date: 2003-03-21

Application number

PT04721843T

Other languages

English (en)

Inventor

John Wijdenes

Helmut Jonuleit

Original Assignee

Biotest Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-21

Filing date

2004-03-19

Publication date

2009-08-28

2004-03-19 Application filed by Biotest Ag filed Critical Biotest Ag

2009-08-28 Publication of PT1654286E publication Critical patent/PT1654286E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT04721843T 2003-03-21 2004-03-19 Anticorpo anti-cd4 humanizado com propriedades imunossupressoras PT1654286E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03290725		2003-03-21
EP03290942A EP1460088A1 (en)	2003-03-21	2003-04-16	Humanized anti-CD4 antibody with immunosuppressive properties

Publications (1)

Publication Number	Publication Date
PT1654286E true PT1654286E (pt)	2009-08-28

Family

ID=32826809

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT09153544T PT2070948E (pt)	2003-03-21	2004-03-19	Anticorpo anti-cd4 humanizado com propriedades imunossupressoras
PT04721843T PT1654286E (pt)	2003-03-21	2004-03-19	Anticorpo anti-cd4 humanizado com propriedades imunossupressoras

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT09153544T PT2070948E (pt)	2003-03-21	2004-03-19	Anticorpo anti-cd4 humanizado com propriedades imunossupressoras

Country Status (21)

Country	Link
US (6)	US7452981B2 (pt)
EP (4)	EP1460088A1 (pt)
JP (1)	JP4491454B2 (pt)
KR (2)	KR101276596B1 (pt)
AT (2)	ATE520716T1 (pt)
AU (1)	AU2004222089B2 (pt)
CA (1)	CA2519620C (pt)
CY (2)	CY1109390T1 (pt)
DE (1)	DE602004021702D1 (pt)
DK (2)	DK2070948T3 (pt)
ES (1)	ES2327523T3 (pt)
HK (2)	HK1132278A1 (pt)
IL (2)	IL169657A (pt)
MX (1)	MXPA05009953A (pt)
NZ (1)	NZ541523A (pt)
PL (2)	PL1654286T3 (pt)
PT (2)	PT2070948E (pt)
RU (1)	RU2375375C2 (pt)
SG (1)	SG159392A1 (pt)
SI (2)	SI1654286T1 (pt)
WO (1)	WO2004083247A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1460088A1 (en)	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
WO2007014420A1 (en) *	2005-08-02	2007-02-08	Centenary Institute Of Cancer Medicine And Cell Biology	Method for identifying regulatory t cells
TW200817438A (en) *	2006-08-17	2008-04-16	Hoffmann La Roche	A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2109770B1 (en) *	2007-02-01	2016-07-06	Universitätsmedizin der Johannes Gutenberg-Universität Mainz	Specific activation of a regulatory T cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction
TW200902544A (en)	2007-03-13	2009-01-16	Hoffmann La Roche	Peptide-complement conjugates
CL2008002092A1 (es)	2007-07-20	2009-05-29	Hoffmann La Roche	Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EP2592147A1 (en)	2007-10-12	2013-05-15	F. Hoffmann-La Roche AG	Protein expression from multiple nucleic acids
AU2009231325B2 (en) *	2008-03-13	2014-09-18	Biotest Ag	Agent for treating disease
SG190627A1 (en) *	2008-03-13	2013-06-28	Biotest Ag	Agent for treating disease
CA2718191C (en)	2008-03-13	2018-05-15	Biotest Ag	Agent for treating disease
MX2010010085A (es) *	2008-03-14	2011-03-29	Biocon Ltd	Un anticuerpo monoclonal y el metodo para su uso.
WO2010019233A1 (en)	2008-08-11	2010-02-18	Nektar Therapeutics	Multi-arm polymeric alkanoate conjugates
PT2341937E (pt) *	2008-09-29	2015-02-18	Biotest Ag	Composição para tratamento de doença
GB0920944D0 (en)	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease
US10894087B2 (en)	2010-12-22	2021-01-19	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en)	2010-12-22	2012-06-28	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en)	2011-05-27	2012-12-06	Nektar Therapeutics	Water - soluble polymer - linked binding moiety and drug compounds
AU2014339897A1 (en)	2013-10-24	2016-04-21	Abbvie Inc.	JAK1 selective inhibitor and uses thereof
WO2015125652A1 (ja) *	2014-02-21	2015-08-27	Ｉｄａｃセラノスティクス株式会社	固形がんの治療剤
JP6830437B2 (ja)	2014-12-10	2021-02-17	リージェンツオブザユニバーシティオブミネソタ	疾患を処置するための遺伝子改変された細胞、組織および臓器
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
MX2018004605A (es)	2015-10-16	2018-11-29	Abbvie Inc	Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11166985B2 (en)	2017-05-12	2021-11-09	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
AU2018367896B2 (en)	2017-05-12	2023-06-01	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
KR20210008502A (ko)	2018-05-11	2021-01-22	크리스퍼 테라퓨틱스 아게	암을 치료하기 위한 방법 및 조성물
AU2019302603A1 (en)	2018-07-13	2021-01-14	Nanjing Legend Biotech Co., Ltd.	Co-receptor systems for treating infectious diseases
MA55797A (fr)	2019-04-30	2022-03-09	Crispr Therapeutics Ag	Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19
JP2024528981A (ja)	2021-08-04	2024-08-01	サナバイオテクノロジー，インコーポレイテッド	Ｃｄ４標的化ウイルスベクターの使用
WO2023114949A1 (en)	2021-12-16	2023-06-22	Sana Biotechnology, Inc.	Methods and systems of particle production
WO2023133595A2 (en)	2022-01-10	2023-07-13	Sana Biotechnology, Inc.	Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en)	2022-02-02	2023-08-10	Sana Biotechnology, Inc.	Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en)	2022-04-01	2023-10-05	Sana Biotechnology, Inc.	Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en)	2022-07-27	2024-02-01	Sana Biotechnology, Inc.	Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en)	2022-08-24	2024-02-29	Sana Biotechnology, Inc.	Delivery of heterologous proteins
WO2024064838A1 (en)	2022-09-21	2024-03-28	Sana Biotechnology, Inc.	Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024112867A1 (en)	2022-11-23	2024-05-30	University Of Georgia Research Foundation, Inc.	Compositions and methods of use thereof for increasing immune responses
WO2024119157A1 (en)	2022-12-02	2024-06-06	Sana Biotechnology, Inc.	Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en)	2023-04-18	2024-10-24	Sana Biotechnology, Inc.	Digital droplet based assay for detecting replication competent lentiviral vector

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT90657B (pt)	1988-05-27	1995-03-01	Ortho Pharma Corp	Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
JPH0768273B2 (ja)	1988-12-02	1995-07-26	カルピス食品工業株式会社	抗ｈｉｖペプチド
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU5656890A (en)	1989-05-02	1990-11-29	Genelabs Incorporated	Chemically modified cd4 peptide fragments having anti-retroviral properties
GB8912497D0 (en)	1989-05-31	1989-07-19	Cobbold Stephen P	Monoclonal antibodies
US5690933A (en) *	1989-05-31	1997-11-25	Glaxo Wellcome Inc.	Monoclonal antibodies for inducing tolerance
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US20020099179A1 (en) *	1989-12-21	2002-07-25	Linda K. Jolliffe	Cdr-grafted antibodies
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
HUT60768A (en)	1990-03-16	1992-10-28	Sandoz Ag	Process for producing cd25 fixing molecules
US7084260B1 (en) *	1996-10-10	2006-08-01	Genpharm International, Inc.	High affinity human antibodies and human antibodies against human antigens
WO1992009305A1 (en) *	1990-11-27	1992-06-11	Biogen, Inc.	Anti cd-4 antibodies blocking hiv-induced syncytia
US7192584B2 (en) *	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) *	1991-07-25	2000-10-24	Idec Pharmaceuticals Corporation	Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5777085A (en) *	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
IL101769A (en)	1992-05-03	2007-02-11	Yeda Res & Dev	Modulation of TNF receptor action
WO1995009652A1 (en)	1993-10-06	1995-04-13	The Kennedy Institute For Rheumatology	Treatment of autoimmune and inflammatory disorders
US6270766B1 (en) *	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
CA2146647C (en)	1992-10-08	2009-05-05	Marc Feldmann	Treatment of autoimmune and inflammatory disorders
DK0614984T4 (da) *	1993-03-05	2010-12-20	Bayer Healthcare Llc	Humane monoklonale anti-TNF-alfa-antistoffer
EP0631783A1 (en)	1993-06-03	1995-01-04	Mitsubishi Chemical Corporation	Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US20020068057A1 (en) *	1994-03-10	2002-06-06	Marc Feldmann	Treatment of autoimmune and inflammatory disorders
EP0840618B1 (en)	1995-05-18	2003-04-23	Ortho-McNeil Pharmaceutical, Inc.	Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies
MX336813B (es)	1996-02-09	2016-02-02	Abbvie Biotechnology Ltd	Anticuerpos humanos que ligan el tnfa humano.
US20010056066A1 (en) *	1996-07-26	2001-12-27	Smithkline Beecham Corporation	Method of treating immune cell mediated systemic diseases
AU4563197A (en)	1996-10-01	1998-04-24	Celltech Therapeutics Limited	Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
US6037454A (en)	1996-11-27	2000-03-14	Genentech, Inc.	Humanized anti-CD11a antibodies
DE19722888A1 (de) *	1997-05-28	1998-12-03	Thomas Prof Dr Huenig	Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
WO2000058362A1 (en)	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
WO2000074718A1 (en) *	1999-06-09	2000-12-14	Immunomedics, Inc.	Immunotherapy of autoimmune disorders using antibodies which target b-cells
WO2001016182A2 (en)	1999-08-27	2001-03-08	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
US7304127B2 (en)	1999-08-27	2007-12-04	United States Of America As Represented By The Secretary, Department Of Health And Human Services	Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
AU2001275186A1 (en)	2000-06-02	2001-12-17	Nicole Kirchhof	Immunotherapeutic method to prevent islet cell rejection
MXPA03002262A (es)	2000-09-18	2003-10-15	Idec Pharma Corp	Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
DE10050935A1 (de) *	2000-10-11	2002-05-02	Tegenero Gmbh	Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
ATE481097T1 (de)	2001-01-16	2010-10-15	Vascular Therapies Llc	Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
AU2002254134B2 (en) *	2001-03-07	2006-06-01	Children's Medical Center Corporation	Method to screen peptide display libraries using minicell display
EP1241249A1 (en) *	2001-03-12	2002-09-18	Gerold Schuler	CD4+CD25+regulatory T cells from human blood
PL363311A1 (en)	2001-04-24	2004-11-15	Merck Patent Gmbh	Combination therapy using anti-angiogenic agents and tnfalpha
DE60238533D1 (de)	2001-06-14	2011-01-20	Cambridge Entpr Ltd	Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
US7541443B2 (en) *	2001-06-14	2009-06-02	Tolerrx, Inc.	Anti-CD4 antibodies
GB2376466A (en)	2001-06-14	2002-12-18	Mark Frewin	TRX1 antibody
ES2392287T3 (es) *	2001-12-04	2012-12-07	Theramab Llc	Péptido o proteína que contiene un bucle C'-D de la familia de receptores de la CD28
DE10212108A1 (de) *	2002-03-13	2003-10-02	Tegenero Ag	Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) *	2002-07-04	2004-01-22	Tegenero Ag	Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
AU2003291625B2 (en)	2002-09-16	2009-10-08	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US7388079B2 (en)	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
US7501494B2 (en) *	2003-01-15	2009-03-10	United Biomedical, Inc.	Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1460088A1 (en)	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
WO2004091657A2 (en) *	2003-04-09	2004-10-28	Genentech, Inc.	Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
GB0314461D0 (en) *	2003-06-20	2003-07-23	Isis Innovation	Suppression of transplant rejection
WO2005019254A1 (en)	2003-08-25	2005-03-03	Pieris Proteolab Ag	Muteins of a bilin-binding protein with affinity for a given target
EP1600164A3 (de)	2003-09-22	2006-05-17	TeGenero AG	Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de)	2003-11-11	2005-06-16	Tegenero Ag	Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
AU2006267090B2 (en) *	2005-07-11	2013-03-07	Provention Bio, Inc.	Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2009231325B2 (en) *	2008-03-13	2014-09-18	Biotest Ag	Agent for treating disease
SG190627A1 (en)	2008-03-13	2013-06-28	Biotest Ag	Agent for treating disease
CA2718191C (en)	2008-03-13	2018-05-15	Biotest Ag	Agent for treating disease
PT2341937E (pt)	2008-09-29	2015-02-18	Biotest Ag	Composição para tratamento de doença
GB0920944D0 (en)	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease

2003
- 2003-04-16 EP EP03290942A patent/EP1460088A1/en not_active Withdrawn
2004
- 2004-03-19 PL PL04721843T patent/PL1654286T3/pl unknown
- 2004-03-19 JP JP2006504748A patent/JP4491454B2/ja not_active Expired - Lifetime
- 2004-03-19 EP EP10179921.1A patent/EP2332991B1/en not_active Expired - Lifetime
- 2004-03-19 DK DK09153544.3T patent/DK2070948T3/da active
- 2004-03-19 DK DK04721843T patent/DK1654286T3/da active
- 2004-03-19 MX MXPA05009953A patent/MXPA05009953A/es active IP Right Grant
- 2004-03-19 PT PT09153544T patent/PT2070948E/pt unknown
- 2004-03-19 EP EP04721843A patent/EP1654286B1/en not_active Expired - Lifetime
- 2004-03-19 SI SI200431225T patent/SI1654286T1/sl unknown
- 2004-03-19 AT AT09153544T patent/ATE520716T1/de active
- 2004-03-19 PT PT04721843T patent/PT1654286E/pt unknown
- 2004-03-19 DE DE602004021702T patent/DE602004021702D1/de not_active Expired - Lifetime
- 2004-03-19 SI SI200431769T patent/SI2070948T1/sl unknown
- 2004-03-19 NZ NZ541523A patent/NZ541523A/en not_active IP Right Cessation
- 2004-03-19 AU AU2004222089A patent/AU2004222089B2/en not_active Ceased
- 2004-03-19 ES ES04721843T patent/ES2327523T3/es not_active Expired - Lifetime
- 2004-03-19 AT AT04721843T patent/ATE434626T1/de active
- 2004-03-19 SG SG200708377-7A patent/SG159392A1/en unknown
- 2004-03-19 PL PL09153544T patent/PL2070948T3/pl unknown
- 2004-03-19 KR KR1020057016180A patent/KR101276596B1/ko active IP Right Grant
- 2004-03-19 CA CA2519620A patent/CA2519620C/en not_active Expired - Lifetime
- 2004-03-19 KR KR1020137007946A patent/KR20130042654A/ko not_active Application Discontinuation
- 2004-03-19 EP EP09153544A patent/EP2070948B1/en not_active Expired - Lifetime
- 2004-03-19 RU RU2005132389/13A patent/RU2375375C2/ru not_active IP Right Cessation
- 2004-03-19 WO PCT/EP2004/002888 patent/WO2004083247A1/en active Application Filing
2005
- 2005-07-13 IL IL169657A patent/IL169657A/en not_active IP Right Cessation
- 2005-09-02 US US11/217,402 patent/US7452981B2/en not_active Expired - Lifetime
2006
- 2006-07-18 HK HK09109579.1A patent/HK1132278A1/xx not_active IP Right Cessation
- 2006-07-18 HK HK06108075.5A patent/HK1088337A1/xx not_active IP Right Cessation
2008
- 2008-10-07 US US12/246,660 patent/US8586715B2/en not_active Expired - Lifetime
2009
- 2009-02-25 US US12/392,556 patent/US8685651B2/en not_active Expired - Fee Related
- 2009-02-25 US US12/392,521 patent/US8673304B2/en not_active Expired - Lifetime
- 2009-02-25 US US12/392,493 patent/US8440806B2/en not_active Expired - Lifetime
- 2009-09-21 CY CY20091100972T patent/CY1109390T1/el unknown
2011
- 2011-05-17 IL IL212949A patent/IL212949A/en not_active IP Right Cessation
- 2011-11-16 CY CY20111101102T patent/CY1112044T1/el unknown
2014
- 2014-02-10 US US14/176,485 patent/US9758581B2/en active Active

Also Published As

Publication number	Publication date
EP2070948B1 (en)	2011-08-17
US20090208497A1 (en)	2009-08-20
US8440806B2 (en)	2013-05-14
HK1088337A1 (en)	2006-11-03
HK1132278A1 (en)	2010-02-19
ATE434626T1 (de)	2009-07-15
CA2519620A1 (en)	2004-09-30
US20100291676A1 (en)	2010-11-18
EP2070948A1 (en)	2009-06-17
EP2332991B1 (en)	2017-04-19
IL212949A0 (en)	2011-07-31
IL169657A (en)	2011-06-30
US8586715B2 (en)	2013-11-19
EP2332991A3 (en)	2012-12-19
IL212949A (en)	2016-06-30
ES2327523T3 (es)	2009-10-30
KR20050111748A (ko)	2005-11-28
KR20130042654A (ko)	2013-04-26
RU2005132389A (ru)	2006-06-27
US20090208496A1 (en)	2009-08-20
SI2070948T1 (sl)	2011-12-30
AU2004222089A1 (en)	2004-09-30
JP2007525156A (ja)	2007-09-06
NZ541523A (en)	2007-07-27
US8685651B2 (en)	2014-04-01
US20140220008A1 (en)	2014-08-07
WO2004083247A1 (en)	2004-09-30
US20060051346A1 (en)	2006-03-09
SG159392A1 (en)	2010-03-30
US8673304B2 (en)	2014-03-18
US20090104190A1 (en)	2009-04-23
DK1654286T3 (da)	2009-08-31
EP2332991A2 (en)	2011-06-15
RU2375375C2 (ru)	2009-12-10
PT2070948E (pt)	2011-09-05
DK2070948T3 (da)	2011-09-12
US9758581B2 (en)	2017-09-12
CA2519620C (en)	2015-02-03
DE602004021702D1 (de)	2009-08-06
EP1654286A1 (en)	2006-05-10
US7452981B2 (en)	2008-11-18
CY1112044T1 (el)	2015-11-04
EP1460088A1 (en)	2004-09-22
PL2070948T3 (pl)	2012-03-30
ATE520716T1 (de)	2011-09-15
PL1654286T3 (pl)	2009-12-31
AU2004222089B2 (en)	2010-12-02
JP4491454B2 (ja)	2010-06-30
SI1654286T1 (sl)	2009-12-31
CY1109390T1 (el)	2014-07-02
KR101276596B1 (ko)	2013-06-21
EP1654286B1 (en)	2009-06-24
MXPA05009953A (es)	2006-03-09

Publication	Publication Date	Title
HK1132278A1 (en)	2010-02-19	Humanized anti-cd4 antibody with immunosuppressive properties
MX2008002161A (es)	2008-04-22	Anticuerpos quimericos con regiones de primate del nuevo mundo.
MX2020001873A (es)	2020-10-22	Agentes de union.
NZ585959A (en)	2012-09-28	Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
NZ602256A (en)	2014-03-28	Monoclonal antibodies against the rgm a protein and uses thereof
NZ604090A (en)	2014-07-25	Human anti-b7rp1 neutralizing antibodies
TW200616662A (en)	2006-06-01	Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
NZ607711A (en)	2014-09-26	Antibodies directed to her-3 and uses thereof
SG151284A1 (en)	2009-04-30	Antibodies against ccr5 and uses thereof
ATE452147T1 (de)	2010-01-15	Antikörper mit korrigierten cdr
NZ594466A (en)	2012-08-31	Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TW200639182A (en)	2006-11-16	Antibody variants and uses thereof
WO2005069970A3 (en)	2009-03-12	Antibody specificity transfer using minimal essential binding determinants
MX2009008143A (es)	2009-10-20	Antienos multivariables acomplejados con anticuerpo monoclonal humanizado de apuntamiento.
NZ621938A (en)	2015-07-31	Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2007087289A3 (en)	2008-10-09	Anti-fcrn antibodies for treatement of auto/allo immune conditions
RS53120B (en)	2014-06-30	ANTAGONISTIC HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE HUMAN LIGHT
NZ595863A (en)	2013-03-28	Antibodies to egfl7 and methods for their use
WO2003087340A3 (en)	2004-03-25	Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
EP1491555A4 (en)	2006-03-15	THE GENE FOR THE LIGHT / HEAVY CHAIN OF THE VARIABLE REGION OF THE MONOCLONAL ANTI-HUMAN HEPATOMAN TONOR HAB18
NZ594668A (en)	2012-10-26	Humanised antibodies with anti-tumour activity
UA94211C2 (ru)	2011-04-26	Выделенное полностью человеческое моноклональное cd3 антитело
WO2006085092A3 (en)	2006-10-12	Methods and uses of antibodies in the purification of interferon
UA98100C2 (ru)	2012-04-25	Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
ZA200506885B (en)	2006-05-31	Humanized anti-CD4 antibody with immunosuppressive properties